ASCO 2026 | BLUESTAR: puxitatug samrotecan safety & efficacy in endometrial or ovarian cancer
Linda Mileshkin
• 30 May 2026
Linda Mileshkin, MBBS, MD, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses updated safety and efficacy data from the Phase I/IIa BLUESTAR trial (NCT05123482) of puxitatug samrotecan, a B7-H4-directed antibody-drug conjugate (ADC), in patients with relapsed/metastatic endometrial or ovarian cancer. The agent demonstrated a favorable safety profile and robust antitumor activity across both tumor types. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
